Abstract: The present invention provides oral pharmaceutical composition comprising Arsenic trioxide and one or more pharmaceutically acceptable excipients for use in the treatment of acute promyelocytic leukemia and other cancers like acute myeloid leukemia. Further, the present invention provides a process for the preparation of the said composition.

Abstract: Disclosed are stable extended release formulations and pharmaceutical compositions of Clozapine that exhibit improved stability under a variety of conditions, as well as processes for the preparation of such formulations and compositions.

Abstract: An extended release pharmaceutical composition of Clozapine The extended release composition of Clozapine provides an extended release pharmaceutical composition having Clozapine, a seal coating, an acidic coating, and an extended release coating. The composition is particularly suitable for dispensing a once-a-day solid oral pharmaceutical formulation which releases a therapeutically effective amount of Clozapine over an extended time period.

Abstract: Disclosed are stable extended release formulations and pharmaceutical compositions of Clozapine that exhibit improved stability under a variety of conditions, as well as processes for the preparation of such formulations and compositions.

Abstract: Disclosed is an extended release pharmaceutical composition of Clozapine, which can be provided as a reservoir type dosage form, and when dosed to a patient once daily achieves at steady state, AUC0-24h, Cmax and Cmin in patient plasma that are within 80 to 125% bioequivalence criteria compared to immediate release Clozapine dosed at the same total daily dose divided twice per day. Further, the pharmaceutical composition of Clozapine can provide once daily dosing regimen in order to improve patient compliance and reduces side effects in patients in need thereof. The pharmaceutical composition further lacks any significant food effect on oral administration.

Abstract: An extended release pharmaceutical composition of Clozapine The extended release composition of Clozapine provides an extended release pharmaceutical composition having Clozapine, a seal coating, an acidic coating, and an extended release coating. The composition is particularly suitable for dispensing a once-a-day solid oral pharmaceutical formulation which releases a therapeutically effective amount of Clozapine over an extended time period.

Abstract: The present invention relates to pharmaceutical composition comprising Everolimus and hot melt extrusion (HME) grade hydroxypropyl methylcellulose, and process for the preparation of the said composition.

Abstract: The present invention relates to an extended release capsules comprising multiple units of Capecitabine, wherein the dissolution of Capecitabine from the said composition is extended up to 12 hours. Further the present invention discloses process for the preparation of the said composition.

Abstract: An extended release pharmaceutical composition of Clozapine The extended release composition of Clozapine provides an extended release pharmaceutical composition having Clozapine, a seal coating, an acidic coating, and an extended release coating. The composition is particularly suitable for dispensing a once-a-day solid oral pharmaceutical formulation which releases a therapeutically effective amount of Clozapine over an extended time period.

Abstract: A pharmaceutical composition of Capecitabine, wherein the composition includes immediate release Capecitabine and extended release Capecitabine. Further disclosed is a process for the preparation of the composition.

Abstract: A stable tablet-in-tablet pharmaceutical composition having fixed dose combinations of cyclophosphamide and capecitabine and one or more pharmaceutically acceptable excipient. As disclosed is a process for the preparation thereof, and a method their use in treating cancer diseases.

Abstract: This present invention relates to pharmaceutical compositions comprising cyclophosphamide alone and/or in combination with one or more pharmaceutical active ingredients and one or more pharmaceutically acceptable excipients wherein the cyclophosphamide has D90 particle size less than 100 microns.

Abstract: The present invention relates to a layered pharmaceutical composition comprising: a first layer of sustained-release bupropion or its pharmaceutically acceptable salts, a second layer of sustained-release naltrexone or its pharmaceutically acceptable salts, with pharmaceutically acceptable excipients, and an intermediate inert layer that provides a time-controlled disintegration to allow separation of two drug layers and maintain their physical integrity as a single tablet. It further provides the methods for preparing the said pharmaceutical compositions for the treatment of obesity-related conditions.

Abstract: This present invention relates to pharmaceutical compositions comprising cyclophosphamide alone and/or in combination with one or more pharmaceutical active ingredients and one or more pharmaceutically acceptable excipients wherein the cyclophosphamide has D90 particle size less than 100 microns.

Abstract: The present invention relates to a stable transdermal gel composition comprising Testosterone, a penetration enhancer, a gelling agent with pharmaceutically acceptable excipients. Further, the invention relates to the method of administering the said transdermal gel and its uses thereof.

Abstract: The present invention relates to a stable pharmaceutical composition of Tigecycline and process for the preparation of the same. The composition comprises Tigecycline and maltose wherein the pH of the bulk solution or solution after reconstitution is in between 3-6.

Abstract: A pharmaceutical compositions having fixed dose combinations of capecitabine and cyclophosphamide, processes for the preparation thereof, and their use to treat cancer diseases.

Abstract: The present invention relates to a stable pharmaceutical composition of Tigecycline and process for the preparation of the same. The composition comprises Tigecycline and maltose wherein the pH of the bulk solution or solution after reconstitution is in between 3-6.

Abstract: The present invention discloses a stable ready-to-use aqueous pharmaceutical preparation containing Cetrorelix or its pharmaceutically acceptable salt, wherein the preparation does not contain any surfactant. Further, the present invention discloses process for the preparation of said stable ready-to-use aqueous pharmaceutical preparation.

Abstract: The present disclosure describes a stable composition of Temsirolimus for parenteral administration. The composition includes BHA or BHT as anti-oxidants and alcoholic solvent. The pH of the composition is below 5.0. The composition also can include a chelating agent and/or a surfactant. A method of producing the composition is also described.